Milestone Pharmaceuticals Inc. (MIST)

The investment case here is defined by a stark disconnect between deteriorating fundamentals and aggressive speculative positioning. Fundamentally, the business is in freefall: the company is burning cash at a rate of roughly $61 million annually, has negative equity, and has suffered a catastrophic 88% decline in share price over the last six years. Despite a recent year-over-year price recovery, the underlying economics remain broken with no path to profitability visible in the near term. However, the options market tells a completely different story. Traders are placing heavy bets on a massive reversal, with open interest concentrated in deep out-of-the-money calls ($1.50-$2.00 strikes) and almost no hedging via puts. This suggests the market is pricing in a binary event—likely a successful clinical trial or regulatory approval—that could send the stock soaring. The low implied volatility on these far-dated calls indicates traders expect the current low price to persist until that catalyst hits. For the investor, this is a high-risk lottery ticket. The short-term outlook is volatile due to this asymmetric options pressure, but the long-term thesis remains weak given the balance sheet implosion and lack of revenue growth. You are not buying a company; you are betting on a specific future milestone that hasn't happened yet.